SCHEMBL25747764

SCHEMBL25747764

NC(=O)c1ccc(-c2ccc(OCCOC=O)c(Br)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 2/20 0.45
▸ PLAU P00749 1/20 0.45
▸ ST14 Q9Y5Y6 1/20 0.45
▸ PDE4A P27815 2/20 0.45
▸ PDE4B Q07343 2/20 0.45
▸ PDE4C Q08493 2/20 0.45
▸ PDE4D Q08499 2/20 0.45
▸ ERN1 O75460 3/20 0.42
▸ MKNK1 Q9BUB5 2/20 0.40
▸ MKNK2 Q9HBH9 2/20 0.40
▸ PARP10 Q53GL7 2/20 0.38
▸ PTPN11 Q06124 1/20 0.38
▸ S1PR1 P21453 1/20 0.38
▸ PTPN1 P18031 1/20 0.38
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ CA14 Q9ULX7 1/20 0.37
▸ CHEK2 O96017 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25040920 0.85 PDE4A (0.45) F2PLAUST14PDE4APDE4B
SCHEMBL25040918 0.85 ERN1 (0.47) PDE4APDE4BPDE4CPDE4DERN1
SCHEMBL25040917 0.85 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DERN1
SCHEMBL25747758 0.82 PDE4A (0.50) F2PLAUST14PDE4APDE4B
SCHEMBL25747834 0.81 CYP1A2 (0.44) —
SCHEMBL25747757 0.78 MMP2 (0.41) CA12CA1CA2CA9
SCHEMBL25040919 0.76 PDE4A (0.40) PDE4APDE4BPDE4CPDE4DERN1
SCHEMBL7439701 0.75 ALDH1A1 (0.60) PDE4APDE4BPDE4CPDE4DERN1
SCHEMBL381038 0.72 PTPN11 (0.56) F2PLAUST14PDE4APDE4B
SCHEMBL27686777 0.70 PTPN11 (0.53) PDE4APDE4BPDE4CPDE4DPTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278956-A1 PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2023-09-07 — — US disclosed
US-20230278956-A1 PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2023-09-07 — — US disclosed
US-11691946-B2 Preparation of Trifarotene and intermediates and polymorphs thereof TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2023-07-04 — — US disclosed
US-11691946-B2 Preparation of Trifarotene and intermediates and polymorphs thereof TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2023-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278956-A1 PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF UGT1A4, TBK1, UGT1A7 F2 105/4885PLAU 2729/4885ST14 989/4885
US-11691946-B2 Preparation of Trifarotene and intermediates and polymorphs thereof UGT1A4, TBK1, UGT1A7 F2 105/4885PLAU 2729/4885ST14 989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback